1
|
Hudock NL, Mani K, Khunsriraksakul C, Walter V, Nekhlyudov L, Wang M, Lehrer EJ, Hudock MR, Liu DJ, Spratt DE, Zaorsky NG. Future trends in incidence and long-term survival of metastatic cancer in the United States. COMMUNICATIONS MEDICINE 2023; 3:76. [PMID: 37244961 DOI: 10.1038/s43856-023-00304-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Accepted: 05/12/2023] [Indexed: 05/29/2023] Open
Abstract
BACKGROUND Previous studies have demonstrated epidemiological trends in individual metastatic cancer subtypes; however, research forecasting long-term incidence trends and projected survivorship of metastatic cancers is lacking. We assess the burden of metastatic cancer to 2040 by (1) characterizing past, current, and forecasted incidence trends, and (2) estimating odds of long-term (5-year) survivorship. METHODS This retrospective, serial cross-sectional, population-based study used registry data from the Surveillance, Epidemiology, and End Results (SEER 9) database. Average annual percentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to 2018. Autoregressive integrating moving average (ARIMA) models were used to forecast the distribution of primary metastatic cancer and metastatic cancer to specific sites from 2019 to 2040 and JoinPoint models were fitted to estimate mean projected annual percentage change (APC). RESULTS The average annual percent change (AAPC) in incidence of metastatic cancer decreased by 0.80 per 100,000 individuals (1988-2018) and we forecast an APC decrease by 0.70 per 100,000 individuals (2018-2040). Analyses predict a decrease in metastases to liver (APC = -3.40, 95% CI [-3.50, -3.30]), lung (APC (2019-2030) = -1.90, 95% CI [-2.90, -1.00]); (2030-2040) = -3.70, 95% CI [-4.60, -2.80]), bone (APC = -4.00, 95% CI [-4.30, -3.70]), and brain (APC = -2.30, 95% CI [-2.60, -2.00]). By 2040, patients with metastatic cancer are predicted to have 46.7% greater odds of long-term survivorship, driven by increasing plurality of patients with more indolent forms of metastatic disease. CONCLUSIONS By 2040, the distribution of metastatic cancer patients is predicted to shift in predominance from invariably fatal to indolent cancers subtypes. Continued research on metastatic cancers is important to guide health policy and clinical intervention efforts, and direct allocations of healthcare resources.
Collapse
Affiliation(s)
- Nicholas L Hudock
- Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA
- Penn State College of Medicine, Hershey, PA, USA
| | - Kyle Mani
- Albert Einstein School of Medicine, Bronx, NY, USA
| | - Chachrit Khunsriraksakul
- Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA
- Penn State College of Medicine, Hershey, PA, USA
- Department of Bioinformatics and Genomics, Penn State College of Medicine, Hershey, PA, USA
| | - Vonn Walter
- Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA
| | - Larissa Nekhlyudov
- Department of Internal Medicine, Harvard Medical School, Boston, MA, USA
| | - Ming Wang
- Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Eric J Lehrer
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Maria R Hudock
- Department of Biomedical Engineering, Columbia University, New York City, NY, USA
- Vagelos College of Physicians & Surgeons, Columbia University, New York City, NY, USA
| | - Dajiang J Liu
- Department of Bioinformatics and Genomics, Penn State College of Medicine, Hershey, PA, USA
- Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA
| | - Daniel E Spratt
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, OH, USA
| | - Nicholas G Zaorsky
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, OH, USA.
| |
Collapse
|
2
|
He H, Liang L, Han D, Xu F, Lyu J. Different Trends in the Incidence and Mortality Rates of Prostate Cancer Between China and the USA: A Joinpoint and Age-Period-Cohort Analysis. Front Med (Lausanne) 2022; 9:824464. [PMID: 35187007 PMCID: PMC8850968 DOI: 10.3389/fmed.2022.824464] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 01/05/2022] [Indexed: 12/25/2022] Open
Abstract
Purpose This study used data from the Global Burden of Disease Study 2019 (GBD 2019) to determine the differences in the incidence and mortality of prostate cancer (PCa) between China and the USA from 1990 to 2019. Method The age-standardized incidence rates (ASIRs) and age-standardized death rates (ASDRs) in China and the USA from 1990 to 2019 were extracted from GBD 2019. Annual percentage changes and relative risks of ASIR and ASDR were calculated using joinpoint regression analysis and age-period-cohort models, respectively. Results The ASIR of PCa in China continually increased from 1990 to 2019, while in the USA it increased from 1990 to 1994 and then continually decreased until 2015, and then slightly increased again until 2019. The ASDR in China did not change, and the trend of ASDR in the USA was similar to the trend of the ASIR in the USA. The incidence of PCa increased with age in China, but decreased after the age of 75 years in the USA. A period effect was present, with the risk of developing PCa increasing continuously over longer time periods. Those born later had a lower risk of PCa or death, indicating a cohort effect. Conclusion PCa is becoming more problematic for Chinese males. Disease trends in the USA indicate that large-scale screening may be beneficial and should be immediately implemented among high-risk groups in China.
Collapse
Affiliation(s)
- Hairong He
- Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.,School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Liang Liang
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Didi Han
- School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Fengshuo Xu
- School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Jun Lyu
- Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.,School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.,Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China
| |
Collapse
|
3
|
Stochastic Sequential Modeling: Toward Improved Prostate Cancer Diagnosis Through Temporal-Ultrasound. Ann Biomed Eng 2020; 49:573-584. [PMID: 32779056 PMCID: PMC7851024 DOI: 10.1007/s10439-020-02585-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Accepted: 07/27/2020] [Indexed: 11/26/2022]
Abstract
Prostate cancer (PCa) is a common, serious form of cancer in men that is still prevalent despite ongoing developments in diagnostic oncology. Current detection methods lead to high rates of inaccurate diagnosis. We present a method to directly model and exploit temporal aspects of temporal enhanced ultrasound (TeUS) for tissue characterization, which improves malignancy prediction. We employ a probabilistic-temporal framework, namely, hidden Markov models (HMMs), for modeling TeUS data obtained from PCa patients. We distinguish malignant from benign tissue by comparing the respective log-likelihood estimates generated by the HMMs. We analyze 1100 TeUS signals acquired from 12 patients. Our results show improved malignancy identification compared to previous results, demonstrating over 85% accuracy and AUC of 0.95. Incorporating temporal information directly into the models leads to improved tissue differentiation in PCa. We expect our method to generalize and be applied to other types of cancer in which temporal-ultrasound can be recorded.
Collapse
|
4
|
Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway. Sci Rep 2019; 9:13284. [PMID: 31527721 PMCID: PMC6746859 DOI: 10.1038/s41598-019-49486-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 08/19/2019] [Indexed: 12/18/2022] Open
Abstract
Elevated fatty acid synthase (FASN) has been reported in both androgen-dependent and -independent prostate cancers. Conventional treatment for prostate cancer is radiotherapy (RT); however, the following radiation-induced radioresistance often causes treatment failure. Upstream proteins of FASN such as Akt and NF-κB are found increased in the radioresistant prostate cancer cells. Nevertheless, whether inhibition of FASN could improve RT outcomes and reverse radiosensitivity of prostate cancer cells is still unknown. Here, we hypothesised that orlistat, a FASN inhibitor, could improve RT outcomes in prostate cancer. Orlistat treatment significantly reduced the S phase population in both androgen-dependent and -independent prostate cancer cells. Combination of orlistat and RT significantly decreased NF-κB activity and related downstream proteins in both prostate cancer cells. Combination effect of orlistat and RT was further investigated in both LNCaP and PC3 tumour-bearing mice. Combination treatment showed the best tumour inhibition compared to that of orlistat alone or RT alone. These results suggest that prostate cancer treated by conventional RT could be improved by orlistat via inhibition of FASN.
Collapse
|
5
|
Zhou X, Jiao D, Dou M, Chen J, Li Z, Li Y, Liu J, Han X. Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2019; 145:1939-1948. [DOI: 10.1007/s00432-019-02962-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 06/28/2019] [Indexed: 02/05/2023]
|
6
|
Wang W, Wang J. Toll-Like Receptor 4 (TLR4)/Cyclooxygenase-2 (COX-2) Regulates Prostate Cancer Cell Proliferation, Migration, and Invasion by NF-κB Activation. Med Sci Monit 2018; 24:5588-5597. [PMID: 30098292 PMCID: PMC6180953 DOI: 10.12659/msm.906857] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Background Toll-like receptor 4 (TLR4)-mediated signaling has been implicated in invasion, metastasis, and survival of various cancers. Activation of TLR4 can promote cyclooxygenase-2 (COX-2) and nuclear factor-κB (NF-κB). However, little is known about the effects of TLR4/COX-2 in prostate cancer (PCa). Material/Methods In our study, TLR4 and COX-2 expressions were detected by quantitative real-time reverse transcription PCR (qRT-PCR) in PCa tissues (n=34). Cell proliferation was measured by Cell Counting Kit-8 (CCK-8) and carboxyfluorescein succinimidyl ester (CFSE) assays. The migration and invasion abilities were detected by wound healing and Transwell assays. qRT-PCR and western blot assays were performed to detect TLR4, COX-2, matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of matrix metalloproteinases (TIMP)-1, epithelial-cadherin (E-cadherin), vimentin, NF-κB (p65), and p-p65 expressions. Results The results revealed that TLR4 and COX-2 were upregulated in PCa tissues; Silencing of TLR4 or COX-2 inhibited PCa cell proliferation, migration, and invasion, and TLR4 siRNAs combined with COX-2 siRNAs synergistically suppressed PCa cell proliferation, migration, and invasion. Silencing of TLR4 or COX-2 also downregulated MMP-2, MMP-9, and E-cadherin expressions, and upregulated TIMP-1 and vimentin expressions. In addition, silencing of TLR4 or COX-2 inhibited p65 phosphorylation and had a synergistic effect. Conclusions We demonstrated that TLR4/COX-2 inhibits PCa cell proliferation, migration, and invasion by regulating NF-κB.
Collapse
Affiliation(s)
- Wei Wang
- Department of Urology Surgery, Tiantai People's Hospital, Taizhou, Zhejiang, China (mainland)
| | - Jiye Wang
- Department of Urology Surgery, Tiantai People's Hospital, Taizhou, Zhejiang, China (mainland)
| |
Collapse
|
7
|
Bhuyan SS, Chandak A, Gupta N, Isharwal S, LaGrange C, Mahmood A, Gentry D. Patient-Provider Communication About Prostate Cancer Screening and Treatment: New Evidence From the Health Information National Trends Survey. Am J Mens Health 2017; 11:134-146. [PMID: 26614441 PMCID: PMC5675184 DOI: 10.1177/1557988315614082] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The American Urological Association, American Cancer Society, and American College of Physicians recommend that patients and providers make a shared decision with respect to prostate-specific antigen (PSA) testing for prostate cancer (PCa). The goal of this study is to determine the extent of patient-provider communication for PSA testing and treatment of PCa and to examine the patient specific factors associated with this communication. Using recent data from the Health Information National Trends Survey, this study examined the association of patient characteristics with four domains of patient-provider communication regarding PSA test and PCa treatment: (1) expert opinion of PSA test, (2) accuracy of PSA test, (3) side effects of PCa treatment, and (4) treatment need of PCa. The current results suggested low level of communication for PSA testing and treatment of PCa across four domains. Less than 10% of the respondents report having communication about all four domains. Patient characteristics like recent medical check-up, regular healthcare provider, global health status, age group, marital status, race, annual household income, and already having undergone a PSA test are associated with patient-provider communication. There are few discussions about PSA testing and PCa treatment options between healthcare providers and their patients, which limits the shared decision-making process for PCa screening and treatment as recommended by the current best practice guidelines. This study helps identify implications for changes in physician practice to adhere with the PSA screening guidelines.
Collapse
Affiliation(s)
| | | | - Niodita Gupta
- University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Chad LaGrange
- University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Dan Gentry
- The University of Memphis, Memphis, TN, USA
| |
Collapse
|
8
|
Shao X, Pan J, Wang Y, Zhu Y, Xu F, Shangguan X, Dong B, Sha J, Chen N, Chen Z, Wang T, Liu S, Xue W. Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 13:1051-1059. [PMID: 27979746 DOI: 10.1016/j.nano.2016.12.001] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 11/20/2016] [Accepted: 12/02/2016] [Indexed: 02/06/2023]
Abstract
Surface-enhanced Raman spectroscopy (SERS) involving expressed prostatic secretion (EPS) and serum was investigated; the objective was to determine if this approach could distinguish prostate cancer from benign prostatic hyperplasia. A total of 120 SERS spectra for EPS and 96 spectra for serum were gathered from patients within a prospective contemporary biopsy cohort. Significant differences in spectra between prostate cancer and benign prostatic hyperplasia were tentatively assigned to component changes in EPS and serum samples. Principal component analysis and linear discriminate analysis were utilized to evaluate the spectral data for EPS and serum, to build diagnostic algorithms. The leave-one-out cross-validation method was used to validate the diagnostic algorithms; it revealed diagnostic sensitivities of 75% and 60%, specificities of 75% and 76.5%, and accuracies of 75% and 68% for EPS and serum, respectively. The results suggest that EPS and serum SERS analysis could be a potential tool for prostate cancer detection.
Collapse
Affiliation(s)
- Xiaoguang Shao
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Jiahua Pan
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Yanqing Wang
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Yinjie Zhu
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Fan Xu
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Xun Shangguan
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Baijun Dong
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Jianjun Sha
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
| | - Na Chen
- Key Laboratory of Specialty Fiber Optics and Optical Access Networks, School of Communication and Information Engineering, Shanghai University, Shanghai, PR China
| | - Zhenyi Chen
- Key Laboratory of Specialty Fiber Optics and Optical Access Networks, School of Communication and Information Engineering, Shanghai University, Shanghai, PR China
| | - Tingyun Wang
- Key Laboratory of Specialty Fiber Optics and Optical Access Networks, School of Communication and Information Engineering, Shanghai University, Shanghai, PR China
| | - Shupeng Liu
- Key Laboratory of Specialty Fiber Optics and Optical Access Networks, School of Communication and Information Engineering, Shanghai University, Shanghai, PR China.
| | - Wei Xue
- Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China.
| |
Collapse
|
9
|
Zaid UB, McAninch JW, Glass AS, Cinman NM, Breyer BN. Presentation, management, and outcomes of complications following prostate cancer therapy. Transl Androl Urol 2016; 3:150-5. [PMID: 26816763 PMCID: PMC4708165 DOI: 10.3978/j.issn.2223-4683.2014.04.05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Objective To characterize complications of prostate cancer therapy and operative management in patients referred to our institution for surgical intervention. Materials and methods Data was abstracted from a retrospectively collected single surgeon database at a large tertiary care referral-based medical center. Variables included age, prostate cancer therapy, complication(s) and their management, and number of operations. Descriptive statistics were used. Results From 2006-2010, 890 patients underwent genitourinary surgery, of which 139 were to treat complications arising from prostate cancer therapy. Complications stemmed from radical prostatectomy (RP) monotherapy, RP and external beam radiation therapy (EBRT) or brachytherapy (BT), EBRT only, BT only, and combination EBRT and BT. Complications included urinary incontinence (UI), urethral strictures, bladder neck contractures, and fistulas. UI and bladder neck contractures were more common in patients treated with RP or RP with EBRT or BT. Strictures and fistulas were common in patients treated with EBRT or BT. Interventions included direct vision internal urethrotomy, artificial urinary sphincter, urethral reconstruction, UroLume urethral stent, urethral sling, repair of fistulas, and balloon dilation. Forty eight percent of patients required multiple operations. The median number of interventions was two. Conclusions We operatively managed patients treated with non-surgical and surgical modalities for prostate cancer. Complications included UI, fistulas, strictures, and bladder neck contractures. These were managed with a variety of operative interventions. As more men undergo treatment for localized disease, more will inevitably have complications stemming from interventions.
Collapse
Affiliation(s)
- Uwais B Zaid
- Department of Urology, University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94117, USA
| | - Jack W McAninch
- Department of Urology, University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94117, USA
| | - Allison S Glass
- Department of Urology, University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94117, USA
| | - Nadya M Cinman
- Department of Urology, University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94117, USA
| | - Benjamin N Breyer
- Department of Urology, University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94117, USA
| |
Collapse
|
10
|
Li S, Guo Z, Liu Z. Surface-enhanced Raman spectroscopy + support vector machine: a new noninvasive method for prostate cancer screening? Expert Rev Anticancer Ther 2015; 15:5-7. [PMID: 25525666 DOI: 10.1586/14737140.2015.992419] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Prostate cancer is one of the most common malignancies of the older males worldwide. Early diagnosis and treatment are important to improve the survival of patients. Recently, we developed a new method for prostate cancer screening: by measuring the serum surface-enhanced Raman spectroscopy of prostate cancer patients and normal subjects, combining with classification algorithms of support vector machines, the measured surface-enhanced Raman spectroscopy spectra are successfully classified with accuracy of 98.1%. Although the practical application faces several difficulties, we believe that this label-free serum surface-enhanced Raman spectroscopy analysis technique combined with support vector machine diagnostic algorithms will become a powerful tool for noninvasive prostate cancer screening in the future.
Collapse
Affiliation(s)
- Shaoxin Li
- Biomedical Engineering Laboratory, Guangdong Medical College, Dongguan 523808, China
| | | | | |
Collapse
|
11
|
Garrett BM, Oliffe JL, Bottorff JL, McKenzie M, Han CS, Ogrodniczuk JS. The value of prostate cancer support groups: a pilot study of primary physicians' perspectives. BMC FAMILY PRACTICE 2014; 15:56. [PMID: 24673983 PMCID: PMC3972516 DOI: 10.1186/1471-2296-15-56] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Accepted: 03/25/2014] [Indexed: 11/10/2022]
Abstract
BACKGROUND In Canada, prostate cancer (PCa) is the most common male cancer, and prostate cancer support groups (PCSGs) have prevailed for more than 20 years providing support to men with PCa and their families. While the format, focus and benefits of attending PCSGs have been reported little is known about primary physicians' (PPs) perceptions of these groups. This article describes Canadian primary physicians' views about face-to-face and web-based PCSGs. METHODS Canadian based primary physicians (n = 140) attending a 2012 Continuing Medical Education Conference participated in a pilot survey questionnaire study. The 56-item questionnaire used in this study included six sets of attitudinal items to measure primary physicians' beliefs about positive and negative influences of PCSGs, reasons for attending PCSGs, the attributes of effective PCSGs, and the value of face-to-face and web-based PCSGs. RESULTS Results showed that PCSGs were positively valued, particularly for information sharing, education and psychosocial support. Poor inclusivity, privacy, and accessibility were identified as potential barriers, and recommendations were made for better marketing and web-based PCSGs to increase engagement with potential attendees. CONCLUSIONS Findings suggest PPs highly valued the role and potential benefits of PCSGs. Information provision and an educational role were perceived as key benefits amid the need to improve local and provincial marketing of PCSGs. The potential for web-based PCSGs to help in the support of PCa patients was also recognized.
Collapse
Affiliation(s)
- Bernard M Garrett
- School of Nursing, University of British Columbia, T201, 2211 Wesbrook Mall, V6T 2B5 Vancouver, BC, Canada.
| | | | | | | | | | | |
Collapse
|
12
|
Harada N, Kimura H, Ono M, Saji H. Preparation of Asymmetric Urea Derivatives that Target Prostate-Specific Membrane Antigen for SPECT Imaging. J Med Chem 2013; 56:7890-901. [DOI: 10.1021/jm400895s] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Naoya Harada
- Department of Patho-Functional
Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
| | - Hiroyuki Kimura
- Department of Patho-Functional
Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
| | - Masahiro Ono
- Department of Patho-Functional
Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
| | - Hideo Saji
- Department of Patho-Functional
Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
| |
Collapse
|
13
|
Lu G, Maresca KP, Hillier SM, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW. Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett 2013; 23:1557-63. [DOI: 10.1016/j.bmcl.2012.09.014] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2012] [Accepted: 09/04/2012] [Indexed: 10/27/2022]
|
14
|
Prostate Specific Antigen Levels and Prostate Cancer Detection Rates in Patients With End Stage Renal Disease. J Urol 2012; 187:2061-5. [DOI: 10.1016/j.juro.2012.01.082] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2011] [Indexed: 11/20/2022]
|
15
|
Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J, Benson MC, Santella RM, Shen J. DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol 2011; 31:187-92. [PMID: 21830905 DOI: 10.1089/dna.2011.1311] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
DNA methylation, a widely used epigenetic mark, has been associated with many tumors. However, few studies have addressed the role of cell-free plasma DNA methylation in discriminating aggressive prostate cancer (PCa) from indolent cases. We conducted a case series and a case-control study among histologically confirmed stage II/III cases and matched controls recruited at Columbia University Medical Center. The aim of this study was to investigate whether plasma DNA methylation levels are appropriate surrogate biomarker of PCa tumor tissue levels and whether these markers are associated with worse clinicopathological tumor characteristics, which correlate with poorer prognosis. Quantitative pyrosequencing was used to detect methylation levels of p16 (CDKN4A), APC, GSTP1, and LINE-1 in 24 pairs of prostate tumor and adjacent tissues, as well as 27 plasma samples of PCa patients and 24 of controls. DNA methylation levels were significantly higher in tumor tissue than in adjacent nontumor tissue for p16 (CDKN4A), GSTP1, and APC; GSTP1 had a higher average percentage methylation in tumor tissue (38.9%) compared with p16 (CDKN4A) (5.9%) and APC (14.5%). GSTP1, p16 (CDKN4A), and APC methylation in tumor tissue was statistically significantly higher for cases with Gleason score ≥7 compared with those with Gleason score <7 [49.0% vs. 21.9% (p=0.01), 6.6% vs. 4.5% (p=0.04), and 19.1% vs. 7.4% (p=0.02), respectively]. Plasma LINE-1 methylation levels were higher in those with higher Gleason (67.6%) than in those with Gleason's below 7 (64.6%, p=0.03). Significant plasma-tissue correlations were observed for GSTP1 and LINE-1 methylation. These data, although preliminary, suggest that aberrant methylation may be a useful marker to identify PCa patients with clinically aggressive disease.
Collapse
Affiliation(s)
- Lissette Delgado-Cruzata
- Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, 650 West 168th Street, New York, NY 10032, USA
| | | | | | | | | | | | | |
Collapse
|